News & Updates

Show Multimedia Only

Fluvoxamine improves fatigue, QoL in long COVID patients

19 Apr 2026 by

Patients with long COVID may derive benefits from treatment with fluvoxamine, which has been shown to reduce fatigue and improve quality of life (QoL) in a study. The use of metformin, on the other hand, shows no significant advantage.

Fluvoxamine improves fatigue, QoL in long COVID patients

19 Apr 2026

Ultrasound-facilitated, catheter-directed thrombolysis beneficial in intermediate-risk PE

18 Apr 2026 by

In the treatment of patients with acute, intermediate-risk pulmonary embolism (PE), administering ultrasound-facilitated, catheter-directed thrombolysis (USCDT) on top of anticoagulation results in better short-term outcomes compared with anticoagulation alone, as shown in the multinational, adaptive-design, open-label HI-PEITHO trial.

Ultrasound-facilitated, catheter-directed thrombolysis beneficial in intermediate-risk PE

18 Apr 2026

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers

17 Apr 2026

The first-in-class KRAS G12D–targeted protein degrader setidegrasib has demonstrated antitumour activity in patients with previously treated advanced non–small-cell lung cancer (NSCLC) or pancreatic ductal adenocarcinoma harbouring the KRAS G12D mutation, according to a phase I study.

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers

17 Apr 2026

Gotistobart a chemo-free option for metastatic sqNSCLC

15 Apr 2026 by

Gotistobart monotherapy elicits an improved and durable antitumour response with a meaningful survival benefit relative to docetaxel in patients with metastatic squamous nonsmall cell lung cancer (sqNSCLC) who experience disease progression on or after anti-PD-(L)1 treatment, as shown by the results of the stage 1 PRESERVE-003 phase III trial.

Gotistobart a chemo-free option for metastatic sqNSCLC

15 Apr 2026

GERD worsens cough in fibrotic interstitial lung disease

15 Apr 2026

In patients with fibrotic interstitial lung disease (ILD), the severity of cough appears to be worse in the presence of gastroesophageal reflux disease (GERD), according to a retrospective study.

GERD worsens cough in fibrotic interstitial lung disease

15 Apr 2026

High-flow oxygen therapy provides no survival advantage in hypoxemic respiratory failure

14 Apr 2026

Oxygen therapy delivered through a high-flow nasal cannula does not appear to significantly lower mortality compared with standard oxygen therapy in patients with hypoxemic respiratory failure, according to an open-label trial.

High-flow oxygen therapy provides no survival advantage in hypoxemic respiratory failure

14 Apr 2026

ILD ups risks of pneumonitis, mortality in patients taking ICIs

14 Apr 2026

Among patients receiving immune checkpoint inhibitors (ICIs), those with interstitial lung disease (ILD) have a significantly greater risk of developing checkpoint inhibitor pneumonitis (CIP) and may experience worse outcomes, including recurrence and death, reveals a study.

ILD ups risks of pneumonitis, mortality in patients taking ICIs

14 Apr 2026

SG sees narrowing male-female gap in lung cancer incidence

10 Apr 2026 by

Singapore is seeing a shift in the incidence of lung cancer, with rising cases among women, including those who are younger and nonsmokers, according to local research.

SG sees narrowing male-female gap in lung cancer incidence

10 Apr 2026

Varenicline shows promise in vaping cessation

09 Apr 2026 by

People who wish to quit vaping may find success with the help of varenicline, which has been found in a recent study to result in numerically higher abstinence rates relative to placebo.

Varenicline shows promise in vaping cessation

09 Apr 2026

Glucose level affects immunotherapy efficacy in NSCLC

02 Apr 2026 by

A study from Israel presented at ELCC 2026 supports the role of glucose control as a modifiable host factor that could improve the effectiveness of immune checkpoint inhibitors in the treatment of non-small cell lung cancer (NSCLC).

Glucose level affects immunotherapy efficacy in NSCLC

02 Apr 2026

News & Updates

Showing Respirology articles

Showing

Specialty:

Fluvoxamine improves fatigue, QoL in long COVID patients

Fluvoxamine improves fatigue, QoL in long COVID patients

Ultrasound-facilitated, catheter-directed thrombolysis beneficial in intermediate-risk PE

Ultrasound-facilitated, catheter-directed thrombolysis beneficial in intermediate-risk PE

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers

Gotistobart a chemo-free option for metastatic sqNSCLC

Gotistobart a chemo-free option for metastatic sqNSCLC

GERD worsens cough in fibrotic interstitial lung disease

GERD worsens cough in fibrotic interstitial lung disease

High-flow oxygen therapy provides no survival advantage in hypoxemic respiratory failure

High-flow oxygen therapy provides no survival advantage in hypoxemic respiratory failure

ILD ups risks of pneumonitis, mortality in patients taking ICIs

ILD ups risks of pneumonitis, mortality in patients taking ICIs

SG sees narrowing male-female gap in lung cancer incidence

SG sees narrowing male-female gap in lung cancer incidence

Varenicline shows promise in vaping cessation

Varenicline shows promise in vaping cessation

Glucose level affects immunotherapy efficacy in NSCLC

Glucose level affects immunotherapy efficacy in NSCLC